Oasmia Pharmaceutical AB (publ) intends to move all of its veterinary assets to the U.S. for further development and commercialization efforts.
The assets include Paccal Vet and Doxophos Vet, the company's products within the field of chemotherapy for companion animals, which they own worldwide distribution rights to, except for Japan.
Oasmia aims to transition the products on a broader scale to a larger number of veterinary clinics. In line with this, Oasmia will transfer all the rights for the two key products to its subsidiary in the U.S to further facilitate strategic development and collaborations.
The company believes it can garner significant market share of the expanding U.S. veterinary industry by reducing the side effects and making its two key products more appealing to general practitioners.
Oasmia expects to implement the strategic changes during 2017.